We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

129 hedge funds and large institutions have $444M invested in Intercept Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 31

33% more call options, than puts

Call options by funds: $22.2M | Put options by funds: $16.7M

15% less funds holding

Funds holding: 151129 (-22)

22% less capital invested

Capital invested by funds: $568M → $444M (-$124M)

65% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 34

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
129
Holders Change
-22
Holders Change %
-14.57%
% of All Funds
2.25%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
12
Increased
53
Reduced
31
Closed
34
Calls
$22.2M
Puts
$16.7M
Net Calls
+$5.47M
Net Calls Change
+$12.6M

ICPT Hedge Fund Activity: Q2 2021 in Review

129 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2021, worth a combined $444M — down 22% from $568M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of ICPT and 12 opened new positions — a net loss of 22 holders — while 31 trimmed existing stakes and 53 added.

The largest buyer was Morgan Stanley, adding an estimated $8.21M. The largest seller was First Trust Advisors, cutting an estimated $50.4M.

  • 129 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2021, down from 151 in Q1 2021.
  • Funds reported $444M of Intercept Pharmaceuticals, Inc. stock for Q2 2021, down 22% quarter-over-quarter.
  • 12 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2021 and 34 closed out, a net change of -22 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2021 was Morgan Stanley, an estimated $8.21M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q2 2021 was First Trust Advisors, an estimated $50.4M sold.

Based on aggregated 13F filings for Q2 2021.